2nd Quarter - Report

OGR for PFIZER INC

Firm
OGR
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376). Issues related to COVID-19 response including vaccines and anti-viral therapies; H.R.7007, COVID Supplemental Appropriations Act, 2022. Issues related to the FY2023 Appropriations Process. Issues related to drug supply chain; H.R.3927/S.2082, MADE in America Act. Issues related to PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022. 340B drug discount program policy issues.

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2082 (117th), H.R. 3927 (117th), H.R. 7007 (117th), H.R. 3 (117th), S. 4348 (117th), H.R. 7667 (117th), H.R. 5376 (117th)

Medicare/Medicaid MMM

Medicare Part D Program; S.912/H.R.1978, Protecting Seniors Through Immunization Act of 2021.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 912 (117th), H.R. 1978 (117th)

Copyright/Patent/Trademark CPT

Issues related to TRIPS Waiver.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.